Defying the Odds: How Engineered CD47 is Transforming Cancer Immunotherapy

by Manisha Kashyap, PhD

(Credit: Simon Bradbrook/Springer Nature Limited)

Introduction: In a significant study published May 15 in Nature, a team of researchers has introduced a novel strategy to enhance the effectiveness of T cell-based cancer therapies. By engineering a variant of the CD47 protein, scientists have found a way to protect therapeutic T cells from being prematurely cleared by the body's immune system, offering new hope in the fight against solid tumors. The open-access article is titled “Engineered CD47 Protects T Cells for Enhanced Antitumour Immunity.”

Login Or Register To Read Full Story